Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia

Annals of Hematology

Volumn 92, Issue 10, 2013, Pages 1379-1388

  Tischer, Johanna ^a   Stemmler, Hans Joachim ^a   Engel, Nicole ^a   Hubmann, Max ^a   Fritsch, Susanne ^a   Prevalsek, Dusan ^a   Schulz, Christoph ^a   Zoellner, Anna K ^a   Bücklein, Veit ^a   Hill, Wolfgang ^a   Ledderose, Georg ^a   Hausmann, Andreas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Allogeneic HSCT; Clofarabine; Cytoreduction; Haploidentical HSCT; Leukemia; Refractory; Relapse

Indexed keywords

CLOFARABINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONFUSION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; FUNGEMIA; HAND FOOT SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HLA MATCHING; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKEMIA REMISSION; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION; VOMITING; WHOLE BODY RADIATION;

ADENINE NUCLEOTIDES; ADULT; AGED; ARABINONUCLEOSIDES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84883862736     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1862-6     Document Type: Article

References (39)

1. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringden O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34(8):721-727. doi: 10.1038/sj.bmt.1704645
2. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675-5687. doi: 10.1200/JCO.2005.07.061
3. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092-1099. doi: 10.1182/blood-2005-10-4165
4. Breccia M, Capria S, Iori AP, Foa R, Alimena G, Meloni G (2010) Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib. Acta Haematol 124(3):150-152. doi: 10.1159/000319630
5. Grigoleit GU, Kapp M, Tan SM, Unzicker C, Einsele H, Mielke S, Topp MS, Stuhler G (2009) Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series. Leuk Lymphoma 50(12):2071-2074. doi: 10.3109/ 10428190903350413
6. Long-Boyle J, Huang J, Rydholm N, Smith A, Orchard P, Tolar J, Jacobson P (2011) Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. J Clin Pharmacol 51(5):679-686. doi: 10.1177/0091270010372519
7. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V (2007) A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110(6):1762-1769. doi: 10.1182/blood-2007-03-081364
8. Robak T, Lech-Maranda E, Korycka A, Robak E (2006) Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 13(26):3165-3189
9. Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354(17):1813-1826. doi: 10.1056/NEJMra052638
10. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M (2005) Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 36(2):157-162. doi: 10.1038/sj.bmt.1705011
11. Bayraktar UD, de Lima M, Ciurea SO (2011) Advances in haploidentical stem cell transplantation. Rev Bras Hematol Hemoter 33(3):237-241. doi: 10.5581/1516-8484.20110060
12. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C et al (1994) Successful engraftment of T-cell-depleted haploidentical three-loci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84(11):3948-3955
13. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14(6):641-650. doi: 10.1016/j.bbmt.2008.03.005
14. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J (2010) Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-436. doi: 10.1038/bmt.2009.189
15. Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, Karasuno T, Okamoto S, Hirabayashi N, Iwato K, Maruta A, Fujimori Y, Furukawa T, Mineishi S, Matsuo K, Hamajima N, Imamura M (2003) Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102(4):1541-1547. doi: 10.1182/blood-2003-02-0430
16. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H, Kato S, Juji T, Kodera Y, Sasazuki T (2007) High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 110(7):2235-2241. doi: 10.1182/blood-2007-02-072405
17. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945-956. doi: 10.1016/j.bbmt.2005.09.004
18. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6):825-828
19. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912-2919. doi: 10.1182/blood-2005-05-2004
20. Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP (1997) Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89(10):3864-3872
21. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V (2008) A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 112(9):3574-3581. doi: 10.1182/blood-2008-02-140095
22. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE (1991) Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 79(4):567-574
23. Schmid C, Schleuning M, Tischer J, Holler E, Haude KH, Braess J, Haferlach C, Baurmann H, Oruzio D, Hahn J, Spiekermann K, Schlimok G, Schwerdtfeger R, Buechner T, Hiddemann W, Kolb HJ (2012) Early allo-SCT for AML with a complex aberrant karyotype - results from a prospective pilot study. Bone Marrow Transplant 47(1):46-53. doi: 10.1038/bmt.2011.15
24. Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P (2006) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24(12):1917-1923. doi: 10.1200/JCO.2005.03.8554
25. Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A (2012) Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol 87(12):1047-1051. doi: 10.1002/ajh.23308
26. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108(1):45-51. doi: 10.1182/blood-2005-08-3294
27. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M (2003) Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21(6):1167-1173
28. Buchholz S, Dammann E, Stadler M, Krauter J, Beutel G, Trummer A, Eder M, Ganser A (2012) Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 88(1):52-60. doi: 10.1111/j.1600-0609.2011.01703.x
29. Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP Jr, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS (2011) A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 17(7):987-994. doi: 10.1016/j.bbmt.2010.10.016
30. Farag SS, Wood LL, Schwartz JE, Srivastava S, Nelson RP Jr, Robertson MJ, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Jones DR (2011) Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia 25(4):599-605. doi: 10.1038/leu.2010.319
31. Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S (2011) Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood 118(15):4258-4264. doi: 10.1182/blood-2011-06-358010
32. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE (2011) Clofarabine +/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900. doi: 10.1016/j.bbmt.2010.09.022
33. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS (2012) Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1819-1826. doi: 10.1016/j.bbmt.2012.06.010
34. Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, Faul C, Guillerm G, Finke J, Huynh A, Schubert J, Kolb HJ, Polge E, Nagler A, Mohty M (2012) Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 89(3):214-219. doi: 10.1111/j.1600-0609.2012.01822.x
35. Locke FL, Artz A, Rich E, Zhang Y, van Besien K, Stock W (2010) Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplant 45(12):1692-1698. doi: 10.1038/bmt.2010.32
36. Kintzel PE, Visser JA, Campbell AD (2011) Clofarabine-associated acute kidney injury and proteinuria. Pharmacotherapy 31(9):923. doi: 10.1592/phco.31.9.923
37. Mineishi S, Magenau J, Tobai H, Pwarode A, Peres EM, Reddy P, Kitko K, Choi S, Erba HP, Kujawski L, Yanik G, Ferrara J, Levine JE (2010) Allogeneic hematopoietic stem cell transplantation with clofarabine/busulfan x 4 (CloBu 4) conditioning exhibits significant anti-tumor activity in non-remission hematologic malignancies, especially in AML. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 35
38. Atimere N, Zriba S, Hicheri Y, Pautas C, Cordonnier C, Maury S (2011) Clofarabine as a potential stimulant of alloreactivity. Bone Marrow Transplant 46(10):1393-1394. doi: 10.1038/bmt.2010.309
39. Maury S, Salomon B, Klatzmann D, Cohen JL (2001) Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood 98(10):3156-3158